跳至主要内容
临床试验/CTRI/2012/12/003173
CTRI/2012/12/003173已完成不适用

Evaluation of dermatological safety of investigational products by primary irritation patch test on healthy volunteers of varied skin types.

ITC RD Centre1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2012年3月10日最近更新:

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
24
试验地点
1
主要终点
To evaluate the dermatological safety of the given investigational product/s on skin of healthy human volunteers by primary irritation patch test

研究概览

简要总结

It is a primary irritation patch test under dermatological control. A patch test under occlusion is carried out using IQ Chambers an inside area of 9X9mm (81mm2) followed by assessment using Draize scale scoring.

24 Healthy human volunteers will be enrolled into the study.

Study duration is 9 days for each subject.

The required quantity of the sample will be put on the upper back of  subjects and closed with IQ chambers prefixed on tape.

This patch will then be applied on the test site i.e. between the scapulae and waist of the subjects. The patch will be kept for 24 hours. After which the patches will be removed and the first observation will be made at 30 minutes of patch removal (0 hr. observation). The further observations will be at 24 hr and 1 week of patch removal.

研究设计

研究类型
Interventional
分配方式
Not Applicable
盲法
Not Applicable

入排标准

年龄范围
18.00 Year(s) 至 55.00 Year(s)(—)
性别
All

入选标准

  • Subjects age group
  • 55 years • Healthy male & female volunteers • Subjects with skin type III to V. • Subjects willing to give a written informed consent. • Subjects willing to maintain the patch test in position for 24 hours • Subject has not participated in a similar investigation in the past two weeks. • Subjects willing to come for regular follow up. • Subjects ready to follow instructions during the study period.

排除标准

  • Infection, allergy on the tested area • Skin allergy antecedents or atopic subjects • Hyper sensitivity to any component of the tested products • Athletes and subjects with history of excessive sweating • Cutaneous disease which may influence the study result • Chronic illness which may influence the cutaneous state.
  • • Subjects on oral corticosteroid with dose 10mg/day • Subjects participating in any other cosmetic or therapeutic trial.
  • • Any history of underlying uncontrolled medical illness including diabetes, liver disease or history of alcoholism, HIV or any other serious medical illness.

结局指标

主要结局

To evaluate the dermatological safety of the given investigational product/s on skin of healthy human volunteers by primary irritation patch test

时间窗: To evaluate the dermatological safety of the given investigational product/s on skin of healthy human volunteers by primary irritation patch test

次要结局

未报告次要终点

研究者

发起方
ITC RD Centre
申办方类型
Other [FMCG Company]

研究点 (1)

Loading locations...

相似试验